What is MOTS-c?
MOTS-c is a small peptide — a short string of 16 amino acids — that your own mitochondria make. Mitochondria are the tiny "power plants" inside your cells that turn food and oxygen into usable energy. For a long time scientists assumed the little bit of DNA inside mitochondria only coded for parts of that energy machinery. MOTS-c was one of the discoveries that changed that picture: it is encoded within the mitochondrial genome and then acts as a signaling molecule, released into the body where it appears to help regulate metabolism.
In humans, MOTS-c is detectable in blood and in skeletal muscle, and research has linked it to exercise and aging: exercise raises the body's own MOTS-c levels in muscle and circulation, and circulating levels tend to differ with age. That observational picture is the reason MOTS-c is interesting to longevity and metabolism researchers. It is important to be clear about what that interest is: MOTS-c is a research molecule. It is not an approved medicine, and the fact that the body makes it does not tell you that injecting more of it is safe, effective, or correctly dosed in people.
How does MOTS-c work in the body?
MOTS-c is unusual in where it comes from. Most of your DNA sits in the cell nucleus, but a small loop of DNA lives inside each mitochondrion, and MOTS-c is encoded within that mitochondrial genome — specifically in the 12S ribosomal RNA region. The cell reads that sequence and produces the 16-amino-acid peptide, which then acts as a signal rather than as a structural part of the energy machinery. That makes MOTS-c one of a small, relatively newly recognized family of "mitochondrial-derived peptides" that appear to let mitochondria send instructions to the rest of the cell.
The mechanism researchers describe runs through metabolism's master switch. In the foundational laboratory work, MOTS-c interfered with the folate cycle and the purine-synthesis pathway tethered to it, causing a metabolic intermediate (AICAR) to build up, which in turn activates AMP-activated protein kinase (AMPK) — the enzyme cells use to sense low energy and respond by burning fuel and improving how the body handles glucose. Under metabolic stress, MOTS-c has also been described as moving into the cell nucleus, where it helps steer the expression of nuclear genes involved in antioxidant defense and metabolism. In plain terms: MOTS-c appears to be a way for mitochondria to nudge the whole cell toward a more efficient, more stress-resistant metabolic state.
Every link in that chain, though, was mapped mainly in cells and mice. Knowing the pathway in detail is genuinely useful science, but it does not tell you that giving extra MOTS-c to a person reproduces those effects, or at what dose — which is the recurring theme of this page, and the reason the mechanistic elegance should not be mistaken for a proven human therapy. A pathway you can draw on a whiteboard and a treatment a person can safely use are separated by years of trials that, for native MOTS-c, simply have not happened.
What does the research actually show?
Most of what is known about giving MOTS-c as a treatment comes from cells and animals, not from people. In the original 2015 study that introduced it, MOTS-c was described as working through the folate cycle to activate AMPK — a master "energy sensor" enzyme that, when switched on, pushes cells toward burning fuel and improving how the body handles glucose. In mice, treatment with MOTS-c helped prevent diet-induced weight gain and improved insulin sensitivity. A later 2021 study showed MOTS-c is induced by exercise and that, in mice, MOTS-c treatment improved physical performance across young, middle-aged, and old animals.
Here is the honest boundary that vendor pages tend to blur: the impressive "benefit" results — weight, insulin sensitivity, running capacity — are in mice. The human findings are observational, meaning researchers measured MOTS-c that the body produced on its own (for example, that exercise raises it); they did not show that injecting MOTS-c improves health outcomes in people. A 2023 scientific review put the state of the field plainly, noting that "no effective method of applying MOTS-c in the clinic has been developed." In short: promising biology, real preclinical signals, and — for actual human therapeutic use — no proof yet.
| Study / model | Finding | Evidence quality |
|---|---|---|
| Lee, Cell Metab 2015 (mouse; 0.5 & 5 mg/kg/day IP) | MOTS-c acts via the folate cycle to activate AMPK; prevented diet-induced weight gain and improved insulin sensitivity. | Mouse (preclinical) |
| Reynolds, Nat Commun 2021 | Exercise induces the body's own MOTS-c in human muscle and blood; MOTS-c treatment improved physical performance in MICE. | Human observational + mouse treatment |
| Zheng, Front Endocrinol 2023 (review) | States "no effective method of applying MOTS-c in the clinic has been developed"; blood MOTS-c runs ~11–21% higher in younger vs older people. | Review (observational human) |
| CB4211, phase 1 (NCT03998514; ~20 adults, 25 mg/day SC, ~4 wk) | Tested a MOTS-c ANALOG, not native MOTS-c: met its safety endpoint with injection-site reactions; the program was later discontinued. | Phase 1 safety — analog, not efficacy |
| USADA / WADA | MOTS-c is not FDA-approved for human use and is prohibited in sport at all times (AMPK activator). | Regulatory status |
Does MOTS-c change with age and exercise?
This is where the human data actually lives, and it is worth understanding precisely because it is so often overstated. MOTS-c is measurable in human blood and skeletal muscle, and two patterns recur. First, levels appear to decline with age: one 2023 review reports that blood MOTS-c in younger people runs roughly 11% higher than in middle-aged people and about 21% higher than in older people. Second, exercise raises it — a 2021 study found that physical activity induces the body's own MOTS-c in human muscle and in circulation, which is part of why MOTS-c is sometimes called an "exercise-mimetic" candidate.
Read carefully, those two facts are observational, and the distinction is everything. They show that MOTS-c is associated with youth and with exercise — not that injecting MOTS-c makes a person younger or fitter. It is entirely possible that MOTS-c is a marker of a healthy, active metabolism rather than a lever you can pull from the outside to create one. The mouse studies hint that the peptide can do real work when administered, but the leap from "young, active people have more of it" and "it helps mice" to "supplementing it benefits humans" is exactly the unproven leap that vendor pages quietly make. The honest version stops where the evidence does: interesting human correlations, encouraging mouse experiments, and no completed human trial of giving MOTS-c that closes the gap between them.
There is a practical corollary worth stating plainly. If higher MOTS-c tracks with being younger and active, the one intervention with solid human evidence for raising your own MOTS-c is the obvious one: exercise. That is a route with a deep safety record and broad, well-documented health benefits, unlike an unregulated injectable whose human dose has never been established. It is a useful reminder that the goal people chase with MOTS-c — a more resilient metabolism — already has an evidence-backed path that does not depend on an unproven research compound.
Is there an official MOTS-c dose?
No. There is no FDA-approved, validated human dose for MOTS-c, because no completed human trials have established what a safe and effective dose even is. That is not a small footnote — it is the whole answer to the "dosing" question. A real therapeutic dose is something that comes out of human dose-finding trials that measure how a compound is absorbed, how long it lasts, what dose produces a benefit, and what dose starts causing harm. That work has not been done for MOTS-c itself.
The closest thing to human testing is a Phase 1 trial (NCT03998514) of CB4211, which is an analog of MOTS-c — a re-engineered, related molecule — not native MOTS-c. The Phase 1b portion gave roughly 20 obese adults with fatty liver disease a fixed 25 mg dose by subcutaneous injection once daily for about four weeks. It was reported as generally safe and well tolerated, met its safety primary endpoint, and showed some exploratory biomarker movement (reductions in the liver enzymes ALT and AST and in glucose) — but it also ran into persistent injection-site reactions, and a Phase 1 safety result is not evidence that the compound works or that any particular dose is correct. It is the first step of a long process, on a different molecule, and notably that program was later discontinued — so it does not give anyone a MOTS-c dose to copy.
The doses you will see quoted in animal research are exactly that — animal doses. The foundational 2015 mouse work used roughly 0.5 mg/kg per day for the longer obesity-prevention experiments and about 5 mg/kg per day for short glucose studies, given as intraperitoneal injections in mice. You cannot translate a mouse mg/kg number into a human protocol; the pharmacokinetics that would let you do that safely have not been characterized for MOTS-c in humans.
What "doses" circulate, and why be skeptical
Search "MOTS-c dosing" and you will find confident-looking charts: figures like 5–10 mg per week split into a few subcutaneous injections, or "0.05–0.15 mg/kg," or fixed "10 mg" protocols with on/off weekly cycles. These read like medical guidance. They are not. They are anecdotal protocols circulated by sellers and forums, not doses established by any human trial or any regulator, and different sources flatly contradict each other — a reliable sign that the number is invented downstream rather than measured.
Be especially skeptical of two moves. The first is borrowing a mouse mg/kg figure and presenting it as a human dose; that is not how dose translation works. The second is pointing to the CB4211 analog trial as if it validated a MOTS-c dose — it tested a different molecule and only for safety. When a "dose" has no approved label, no completed efficacy trial, and no agreement between sources behind it, the right reading is not "the dose is X" but "there is no established dose, and these numbers carry unknown risk."
Risks + unknowns
Because there are no completed human safety trials of MOTS-c itself, its true side-effect profile, safe dose range, drug interactions, and long-term effects in people are genuinely unknown. The analog that was tested in humans showed injection-site reactions, which is at least a hint that the injection experience is not nothing — but that tells you about a different molecule, not native MOTS-c.
There is a second, separate risk that has nothing to do with the peptide's biology: product quality. MOTS-c is sold research-use-only and labeled "not for human consumption." Material sold that way is not manufactured or released as a medicine, so its identity, purity, dose accuracy, sterility, and endotoxin level are not guaranteed. For anything injected, contamination is a real category of harm independent of whatever the peptide may or may not do. Two more facts worth knowing plainly: MOTS-c is not FDA-approved for any use, and it is prohibited in sport at all times under the World Anti-Doping Agency list (as an AMPK activator), so a tested athlete using it risks a doping violation with no therapeutic-use exemption available.
Who to ask
If you are weighing anything involving MOTS-c, the person to talk to is a licensed clinician — not a vendor, a forum, or a dosing chart. A physician can put the actual evidence (and its limits) in the context of your health, explain why an unapproved research compound carries unknowns that an approved medicine does not, and discuss safer, evidence-backed ways to pursue the same goals, such as the metabolic and mitochondrial benefits of exercise that raise your own MOTS-c naturally.
A clinician is also the right safeguard if a genuine investigational protocol is involved, ideally one with proper oversight. The honest summary to bring into that conversation is simple: MOTS-c is experimental, has no validated human dose, and "research-use-only" is not the same as "safe and ready to use."
Tracking a clinician-supervised protocol on PeptidePanel
PeptidePanel does not sell, source, supply, endorse, or prescribe MOTS-c or any compound, and nothing here is medical advice. If a licensed clinician is supervising an investigational protocol, tracking it with the same rigor you would apply to an approved therapy is sensible: a dose log with timestamps, the metabolic biomarkers your clinician chooses to follow, weight and body-composition trends, and any side effects.
PeptidePanel is the neutral monitoring layer for that record-keeping. It logs the protocol exactly as your clinician directs, charts results against reference ranges over time, and helps you and your prescriber see how the measured numbers actually move — turning scattered anecdote into a record you can both review.